International Nonproprietary Name (INN): Acidum Tranexamicum
Pharmacological Group: Antihemorrhagic and Hemostatic Agents
Pharmacotherapeutic Group: Antifibrinolytic Agent
Each tablet or 5 mL ampoule contains:
Tranestat (tranexamic acid) is an antifibrinolytic agent that inhibits the activation of plasminogen to plasmin.
Tranestat stabilizes fibrin structures by preventing the final breakdown of hemostatic fibrin by plasmin, thereby reducing severe or recurrent bleeding caused by defective fibrin formation or excessive fibrin degradation.
In addition, Tranestat promotes collagen synthesis and granulation tissue formation, likely by preserving the fibrin matrix.
Prevention of bleeding following surgery or trauma, including:
Also indicated for:
Tranexamic acid is generally well tolerated. Possible adverse effects include:
Tranestat may be administered orally, by slow intravenous injection, or by continuous intravenous infusion.
After several days, injectable therapy is usually replaced with oral treatment.
Adults:
Children:
Keep out of the reach of children.
